Pharmacogenomics (PGx) is a branch of precision medicine that studies how an individual’s genetic makeup affects their response to drugs. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to tailor drug treatments for individual patients, improving efficacy and reducing adverse effects. By analyzing genetic variations, pharmacogenomics helps in developing personalized treatment plans, minimizing trial-and-error prescriptions, and optimizing drug dosages.
Market Size
The global Pharmacogenomics (PGx) market is projected to grow from US$ 8,569.5 million in 2024 to US$ 14,590 million by 2030, reflecting a CAGR of 9.3% during the forecast period.
The rising adoption of precision medicine, technological advancements in genomic research, and the increasing prevalence of chronic diseases are driving market expansion. In 2023, North America accounted for the largest market share due to well-established healthcare infrastructure and robust investment in genomics research.
Market Dynamics (Drivers, Restraints, Opportunities, and Challenges)
Drivers:
-
Rising Demand for Personalized Medicine – The shift towards individualized treatment plans is boosting the adoption of PGx.
-
Technological Advancements – The development of next-generation sequencing (NGS) and CRISPR-based gene editing enhances PGx applications.
-
Increasing Prevalence of Chronic Diseases – Cardiovascular diseases, cancer, and neurological disorders drive the need for effective drug response assessments.
-
Growing Government and Private Funding – Investments in genomic research propel market growth.
-
Expanding Applications Beyond Oncology – PGx is now widely used in cardiology, neurology, infectious diseases, and psychiatric disorders.
Restraints:
-
High Cost of PGx Testing – Expensive genetic testing limits accessibility.
-
Regulatory and Ethical Concerns – Privacy concerns and stringent regulations hinder market adoption.
-
Lack of Standardization – Variability in testing methods impacts consistency.
-
Limited Awareness and Adoption in Developing Regions – Emerging markets face challenges in PGx integration.
Opportunities:
-
Integration of AI and Big Data in PGx Research – AI-driven analytics can accelerate drug response predictions.
-
Expansion in Emerging Markets – Asia-Pacific and Latin America offer untapped growth potential.
-
Strategic Collaborations Between Pharma and Biotech Firms – Partnerships enhance research capabilities and commercial success.
Challenges:
- Complex Data Interpretation – Requires specialized expertise to analyze genetic data.
- Reimbursement Issues – Insurance coverage for PGx testing remains inconsistent.
- Resistance from Traditional Practitioners – Lack of clinical guidelines affects physician adoption.
Regional Analysis
North America
-
Largest market share due to robust R&D investment and early adoption of PGx.
-
Presence of leading pharmaceutical and biotech companies.
-
Favorable government policies supporting genomics research.
Europe
-
Strong regulatory framework promoting precision medicine.
-
Increasing adoption of PGx in oncology and neurology.
-
Rising collaborations between academic institutions and industry players.
Asia-Pacific
-
Fastest-growing region due to government initiatives in genomic research.
-
Expanding healthcare infrastructure and increasing awareness of PGx.
-
Growing number of pharmaceutical companies investing in personalized medicine.
South America
Middle East & Africa
Competitor Analysis
Key players in the Pharmacogenomics market include:
- Abbott Laboratories
- Affymetrix, Inc.
- AstraZeneca
- Illumina, Inc.
- Myriad Genetics, Inc.
- Pfizer, Inc.
- Qiagen, Inc.
- Thermo Fisher Scientific
These companies focus on strategic partnerships, acquisitions, and product innovations to maintain market dominance. R&D investments in sequencing technologies and personalized medicine continue to drive competition.
Market Segmentation (by Application)
- Cardiovascular Diseases (CVD) – PGx helps in optimizing drug efficacy for heart-related conditions.
- Central Nervous System (CNS) Disorders – Used for psychiatric and neurological diseases.
- Cancer/Oncology – Key area of PGx application in targeted therapies.
- Infectious Diseases – Enhancing drug response in viral and bacterial infections.
- Other – Including autoimmune diseases, metabolic disorders, and pain management.
Market Segmentation (by Type)
- Polymerase Chain Reaction (PCR) – Widely used for detecting genetic mutations.
- Microarray – Enables large-scale genetic analysis.
- Sequencing – Next-generation sequencing (NGS) drives advancements in PGx.
- Other – Includes electrophoresis and mass spectrometry techniques.
Key Company
- Abbott Laboratories
- Affymetrix, Inc.
- Assurex Health, Inc
- AstraZeneca
- GeneDX
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Pathway Genomics
- Pfizer, Inc
- Qiagen, Inc.
- Rocheg
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific
-
Transgenomic, Inc.
Geographic Segmentation
- North America: USA, Canada, Mexico
- Europe: Germany, UK, France, Russia, Italy, Rest of Europe
- Asia-Pacific: China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific
- South America: Brazil, Argentina, Columbia, Rest of South America
- Middle East and Africa: Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA
FAQ Section
What is the current market size of the Pharmacogenomics (PGx) market?
- The market is valued at US$ 8,569.5 million in 2024 and is expected to reach US$ 14,590 million by 2030, growing at a CAGR of 9.3%.
Which are the key companies operating in the Pharmacogenomics (PGx) market?
- Major players include Abbott Laboratories, AstraZeneca, Illumina, Myriad Genetics, Pfizer, Qiagen, and Thermo Fisher Scientific.
What are the key growth drivers in the Pharmacogenomics (PGx) market?
- Key drivers include the rise in personalized medicine, technological advancements in genomics, and increasing prevalence of chronic diseases.
Which regions dominate the Pharmacogenomics (PGx) market?
- North America leads due to high R&D investment, while Asia-Pacific is the fastest-growing region.
What are the emerging trends in the Pharmacogenomics (PGx) market?
- Trends include AI integration in genomics, increasing collaborations, and expansion of PGx applications beyond oncology.
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Pharmacogenomics (PGx) Market
- Overview of the regional outlook of the Pharmacogenomics (PGx) Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Pharmacogenomics (PGx) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Pharmacogenomics (PGx)
1.2 Key Market Segments
1.2.1 Pharmacogenomics (PGx) Segment by Type
1.2.2 Pharmacogenomics (PGx) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Pharmacogenomics (PGx) Market Overview
2.1 Global Market Overview
2.1.1 Global Pharmacogenomics (PGx) Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Pharmacogenomics (PGx) Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Pharmacogenomics (PGx) Market Competitive Landscape
3.1 Global Pharmacogenomics (PGx) Sales by Manufacturers (2019-2024)
3.2 Global Pharmacogenomics (PGx) Revenue Market Share by Manufacturers (2019-2024)
3.3 Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Pharmacogenomics (PGx) Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Pharmacogenomics (PGx) Sales Sites, Area Served, Product Type
3.6 Pharmacogenomics (PGx) Market Competitive Situation and Trends
3.6.1 Pharmacogenomics (PGx) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Pharmacogenomics (PGx) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Pharmacogenomics (PGx) Industry Chain Analysis
4.1 Pharmacogenomics (PGx) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Pharmacogenomics (PGx) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Pharmacogenomics (PGx) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Pharmacogenomics (PGx) Sales Market Share by Type (2019-2024)
6.3 Global Pharmacogenomics (PGx) Market Size Market Share by Type (2019-2024)
6.4 Global Pharmacogenomics (PGx) Price by Type (2019-2024)
7 Pharmacogenomics (PGx) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Pharmacogenomics (PGx) Market Sales by Application (2019-2024)
7.3 Global Pharmacogenomics (PGx) Market Size (M USD) by Application (2019-2024)
7.4 Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2019-2024)
8 Pharmacogenomics (PGx) Market Segmentation by Region
8.1 Global Pharmacogenomics (PGx) Sales by Region
8.1.1 Global Pharmacogenomics (PGx) Sales by Region
8.1.2 Global Pharmacogenomics (PGx) Sales Market Share by Region
8.2 North America
8.2.1 North America Pharmacogenomics (PGx) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Pharmacogenomics (PGx) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Pharmacogenomics (PGx) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Pharmacogenomics (PGx) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Pharmacogenomics (PGx) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Abbott Laboratories
9.1.1 Abbott Laboratories Pharmacogenomics (PGx) Basic Information
9.1.2 Abbott Laboratories Pharmacogenomics (PGx) Product Overview
9.1.3 Abbott Laboratories Pharmacogenomics (PGx) Product Market Performance
9.1.4 Abbott Laboratories Business Overview
9.1.5 Abbott Laboratories Pharmacogenomics (PGx) SWOT Analysis
9.1.6 Abbott Laboratories Recent Developments
9.2 Affymetrix, Inc.
9.2.1 Affymetrix, Inc. Pharmacogenomics (PGx) Basic Information
9.2.2 Affymetrix, Inc. Pharmacogenomics (PGx) Product Overview
9.2.3 Affymetrix, Inc. Pharmacogenomics (PGx) Product Market Performance
9.2.4 Affymetrix, Inc. Business Overview
9.2.5 Affymetrix, Inc. Pharmacogenomics (PGx) SWOT Analysis
9.2.6 Affymetrix, Inc. Recent Developments
9.3 Assurex Health, Inc
9.3.1 Assurex Health, Inc Pharmacogenomics (PGx) Basic Information
9.3.2 Assurex Health, Inc Pharmacogenomics (PGx) Product Overview
9.3.3 Assurex Health, Inc Pharmacogenomics (PGx) Product Market Performance
9.3.4 Assurex Health, Inc Pharmacogenomics (PGx) SWOT Analysis
9.3.5 Assurex Health, Inc Business Overview
9.3.6 Assurex Health, Inc Recent Developments
9.4 Astrazeneca
9.4.1 Astrazeneca Pharmacogenomics (PGx) Basic Information
9.4.2 Astrazeneca Pharmacogenomics (PGx) Product Overview
9.4.3 Astrazeneca Pharmacogenomics (PGx) Product Market Performance
9.4.4 Astrazeneca Business Overview
9.4.5 Astrazeneca Recent Developments
9.5 GeneDX
9.5.1 GeneDX Pharmacogenomics (PGx) Basic Information
9.5.2 GeneDX Pharmacogenomics (PGx) Product Overview
9.5.3 GeneDX Pharmacogenomics (PGx) Product Market Performance
9.5.4 GeneDX Business Overview
9.5.5 GeneDX Recent Developments
9.6 Illumina, Inc.
9.6.1 Illumina, Inc. Pharmacogenomics (PGx) Basic Information
9.6.2 Illumina, Inc. Pharmacogenomics (PGx) Product Overview
9.6.3 Illumina, Inc. Pharmacogenomics (PGx) Product Market Performance
9.6.4 Illumina, Inc. Business Overview
9.6.5 Illumina, Inc. Recent Developments
9.7 Laboratory Corporation of America Holdings
9.7.1 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Basic Information
9.7.2 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Overview
9.7.3 Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Market Performance
9.7.4 Laboratory Corporation of America Holdings Business Overview
9.7.5 Laboratory Corporation of America Holdings Recent Developments
9.8 Myriad Genetics, Inc.
9.8.1 Myriad Genetics, Inc. Pharmacogenomics (PGx) Basic Information
9.8.2 Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Overview
9.8.3 Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Market Performance
9.8.4 Myriad Genetics, Inc. Business Overview
9.8.5 Myriad Genetics, Inc. Recent Developments
9.9 Pathway Genomics
9.9.1 Pathway Genomics Pharmacogenomics (PGx) Basic Information
9.9.2 Pathway Genomics Pharmacogenomics (PGx) Product Overview
9.9.3 Pathway Genomics Pharmacogenomics (PGx) Product Market Performance
9.9.4 Pathway Genomics Business Overview
9.9.5 Pathway Genomics Recent Developments
9.10 Pfizer, Inc
9.10.1 Pfizer, Inc Pharmacogenomics (PGx) Basic Information
9.10.2 Pfizer, Inc Pharmacogenomics (PGx) Product Overview
9.10.3 Pfizer, Inc Pharmacogenomics (PGx) Product Market Performance
9.10.4 Pfizer, Inc Business Overview
9.10.5 Pfizer, Inc Recent Developments
9.11 Qiagen, Inc.
9.11.1 Qiagen, Inc. Pharmacogenomics (PGx) Basic Information
9.11.2 Qiagen, Inc. Pharmacogenomics (PGx) Product Overview
9.11.3 Qiagen, Inc. Pharmacogenomics (PGx) Product Market Performance
9.11.4 Qiagen, Inc. Business Overview
9.11.5 Qiagen, Inc. Recent Developments
9.12 Rocheg
9.12.1 Rocheg Pharmacogenomics (PGx) Basic Information
9.12.2 Rocheg Pharmacogenomics (PGx) Product Overview
9.12.3 Rocheg Pharmacogenomics (PGx) Product Market Performance
9.12.4 Rocheg Business Overview
9.12.5 Rocheg Recent Developments
9.13 Teva Pharmaceutical Industries Ltd.
9.13.1 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Basic Information
9.13.2 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Overview
9.13.3 Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Market Performance
9.13.4 Teva Pharmaceutical Industries Ltd. Business Overview
9.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9.14 Thermo Fisher Scientific
9.14.1 Thermo Fisher Scientific Pharmacogenomics (PGx) Basic Information
9.14.2 Thermo Fisher Scientific Pharmacogenomics (PGx) Product Overview
9.14.3 Thermo Fisher Scientific Pharmacogenomics (PGx) Product Market Performance
9.14.4 Thermo Fisher Scientific Business Overview
9.14.5 Thermo Fisher Scientific Recent Developments
9.15 Transgenomic, Inc.
9.15.1 Transgenomic, Inc. Pharmacogenomics (PGx) Basic Information
9.15.2 Transgenomic, Inc. Pharmacogenomics (PGx) Product Overview
9.15.3 Transgenomic, Inc. Pharmacogenomics (PGx) Product Market Performance
9.15.4 Transgenomic, Inc. Business Overview
9.15.5 Transgenomic, Inc. Recent Developments
10 Pharmacogenomics (PGx) Market Forecast by Region
10.1 Global Pharmacogenomics (PGx) Market Size Forecast
10.2 Global Pharmacogenomics (PGx) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Pharmacogenomics (PGx) Market Size Forecast by Country
10.2.3 Asia Pacific Pharmacogenomics (PGx) Market Size Forecast by Region
10.2.4 South America Pharmacogenomics (PGx) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Pharmacogenomics (PGx) by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Pharmacogenomics (PGx) Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Pharmacogenomics (PGx) by Type (2025-2030)
11.1.2 Global Pharmacogenomics (PGx) Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Pharmacogenomics (PGx) by Type (2025-2030)
11.2 Global Pharmacogenomics (PGx) Market Forecast by Application (2025-2030)
11.2.1 Global Pharmacogenomics (PGx) Sales (K Units) Forecast by Application
11.2.2 Global Pharmacogenomics (PGx) Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Pharmacogenomics (PGx) Market Size Comparison by Region (M USD)
Table 5. Global Pharmacogenomics (PGx) Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Pharmacogenomics (PGx) Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Pharmacogenomics (PGx) Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Pharmacogenomics (PGx) Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics (PGx) as of 2022)
Table 10. Global Market Pharmacogenomics (PGx) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Pharmacogenomics (PGx) Sales Sites and Area Served
Table 12. Manufacturers Pharmacogenomics (PGx) Product Type
Table 13. Global Pharmacogenomics (PGx) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Pharmacogenomics (PGx)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Pharmacogenomics (PGx) Market Challenges
Table 22. Global Pharmacogenomics (PGx) Sales by Type (K Units)
Table 23. Global Pharmacogenomics (PGx) Market Size by Type (M USD)
Table 24. Global Pharmacogenomics (PGx) Sales (K Units) by Type (2019-2024)
Table 25. Global Pharmacogenomics (PGx) Sales Market Share by Type (2019-2024)
Table 26. Global Pharmacogenomics (PGx) Market Size (M USD) by Type (2019-2024)
Table 27. Global Pharmacogenomics (PGx) Market Size Share by Type (2019-2024)
Table 28. Global Pharmacogenomics (PGx) Price (USD/Unit) by Type (2019-2024)
Table 29. Global Pharmacogenomics (PGx) Sales (K Units) by Application
Table 30. Global Pharmacogenomics (PGx) Market Size by Application
Table 31. Global Pharmacogenomics (PGx) Sales by Application (2019-2024) & (K Units)
Table 32. Global Pharmacogenomics (PGx) Sales Market Share by Application (2019-2024)
Table 33. Global Pharmacogenomics (PGx) Sales by Application (2019-2024) & (M USD)
Table 34. Global Pharmacogenomics (PGx) Market Share by Application (2019-2024)
Table 35. Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2019-2024)
Table 36. Global Pharmacogenomics (PGx) Sales by Region (2019-2024) & (K Units)
Table 37. Global Pharmacogenomics (PGx) Sales Market Share by Region (2019-2024)
Table 38. North America Pharmacogenomics (PGx) Sales by Country (2019-2024) & (K Units)
Table 39. Europe Pharmacogenomics (PGx) Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Pharmacogenomics (PGx) Sales by Region (2019-2024) & (K Units)
Table 41. South America Pharmacogenomics (PGx) Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Pharmacogenomics (PGx) Sales by Region (2019-2024) & (K Units)
Table 43. Abbott Laboratories Pharmacogenomics (PGx) Basic Information
Table 44. Abbott Laboratories Pharmacogenomics (PGx) Product Overview
Table 45. Abbott Laboratories Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Abbott Laboratories Business Overview
Table 47. Abbott Laboratories Pharmacogenomics (PGx) SWOT Analysis
Table 48. Abbott Laboratories Recent Developments
Table 49. Affymetrix, Inc. Pharmacogenomics (PGx) Basic Information
Table 50. Affymetrix, Inc. Pharmacogenomics (PGx) Product Overview
Table 51. Affymetrix, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Affymetrix, Inc. Business Overview
Table 53. Affymetrix, Inc. Pharmacogenomics (PGx) SWOT Analysis
Table 54. Affymetrix, Inc. Recent Developments
Table 55. Assurex Health, Inc Pharmacogenomics (PGx) Basic Information
Table 56. Assurex Health, Inc Pharmacogenomics (PGx) Product Overview
Table 57. Assurex Health, Inc Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Assurex Health, Inc Pharmacogenomics (PGx) SWOT Analysis
Table 59. Assurex Health, Inc Business Overview
Table 60. Assurex Health, Inc Recent Developments
Table 61. Astrazeneca Pharmacogenomics (PGx) Basic Information
Table 62. Astrazeneca Pharmacogenomics (PGx) Product Overview
Table 63. Astrazeneca Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Astrazeneca Business Overview
Table 65. Astrazeneca Recent Developments
Table 66. GeneDX Pharmacogenomics (PGx) Basic Information
Table 67. GeneDX Pharmacogenomics (PGx) Product Overview
Table 68. GeneDX Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. GeneDX Business Overview
Table 70. GeneDX Recent Developments
Table 71. Illumina, Inc. Pharmacogenomics (PGx) Basic Information
Table 72. Illumina, Inc. Pharmacogenomics (PGx) Product Overview
Table 73. Illumina, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Illumina, Inc. Business Overview
Table 75. Illumina, Inc. Recent Developments
Table 76. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Basic Information
Table 77. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Product Overview
Table 78. Laboratory Corporation of America Holdings Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Laboratory Corporation of America Holdings Business Overview
Table 80. Laboratory Corporation of America Holdings Recent Developments
Table 81. Myriad Genetics, Inc. Pharmacogenomics (PGx) Basic Information
Table 82. Myriad Genetics, Inc. Pharmacogenomics (PGx) Product Overview
Table 83. Myriad Genetics, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Myriad Genetics, Inc. Business Overview
Table 85. Myriad Genetics, Inc. Recent Developments
Table 86. Pathway Genomics Pharmacogenomics (PGx) Basic Information
Table 87. Pathway Genomics Pharmacogenomics (PGx) Product Overview
Table 88. Pathway Genomics Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Pathway Genomics Business Overview
Table 90. Pathway Genomics Recent Developments
Table 91. Pfizer, Inc Pharmacogenomics (PGx) Basic Information
Table 92. Pfizer, Inc Pharmacogenomics (PGx) Product Overview
Table 93. Pfizer, Inc Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Pfizer, Inc Business Overview
Table 95. Pfizer, Inc Recent Developments
Table 96. Qiagen, Inc. Pharmacogenomics (PGx) Basic Information
Table 97. Qiagen, Inc. Pharmacogenomics (PGx) Product Overview
Table 98. Qiagen, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Qiagen, Inc. Business Overview
Table 100. Qiagen, Inc. Recent Developments
Table 101. Rocheg Pharmacogenomics (PGx) Basic Information
Table 102. Rocheg Pharmacogenomics (PGx) Product Overview
Table 103. Rocheg Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Rocheg Business Overview
Table 105. Rocheg Recent Developments
Table 106. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Basic Information
Table 107. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Product Overview
Table 108. Teva Pharmaceutical Industries Ltd. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Teva Pharmaceutical Industries Ltd. Business Overview
Table 110. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 111. Thermo Fisher Scientific Pharmacogenomics (PGx) Basic Information
Table 112. Thermo Fisher Scientific Pharmacogenomics (PGx) Product Overview
Table 113. Thermo Fisher Scientific Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Thermo Fisher Scientific Business Overview
Table 115. Thermo Fisher Scientific Recent Developments
Table 116. Transgenomic, Inc. Pharmacogenomics (PGx) Basic Information
Table 117. Transgenomic, Inc. Pharmacogenomics (PGx) Product Overview
Table 118. Transgenomic, Inc. Pharmacogenomics (PGx) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Transgenomic, Inc. Business Overview
Table 120. Transgenomic, Inc. Recent Developments
Table 121. Global Pharmacogenomics (PGx) Sales Forecast by Region (2025-2030) & (K Units)
Table 122. Global Pharmacogenomics (PGx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 123. North America Pharmacogenomics (PGx) Sales Forecast by Country (2025-2030) & (K Units)
Table 124. North America Pharmacogenomics (PGx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 125. Europe Pharmacogenomics (PGx) Sales Forecast by Country (2025-2030) & (K Units)
Table 126. Europe Pharmacogenomics (PGx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 127. Asia Pacific Pharmacogenomics (PGx) Sales Forecast by Region (2025-2030) & (K Units)
Table 128. Asia Pacific Pharmacogenomics (PGx) Market Size Forecast by Region (2025-2030) & (M USD)
Table 129. South America Pharmacogenomics (PGx) Sales Forecast by Country (2025-2030) & (K Units)
Table 130. South America Pharmacogenomics (PGx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 131. Middle East and Africa Pharmacogenomics (PGx) Consumption Forecast by Country (2025-2030) & (Units)
Table 132. Middle East and Africa Pharmacogenomics (PGx) Market Size Forecast by Country (2025-2030) & (M USD)
Table 133. Global Pharmacogenomics (PGx) Sales Forecast by Type (2025-2030) & (K Units)
Table 134. Global Pharmacogenomics (PGx) Market Size Forecast by Type (2025-2030) & (M USD)
Table 135. Global Pharmacogenomics (PGx) Price Forecast by Type (2025-2030) & (USD/Unit)
Table 136. Global Pharmacogenomics (PGx) Sales (K Units) Forecast by Application (2025-2030)
Table 137. Global Pharmacogenomics (PGx) Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Pharmacogenomics (PGx)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Pharmacogenomics (PGx) Market Size (M USD), 2019-2030
Figure 5. Global Pharmacogenomics (PGx) Market Size (M USD) (2019-2030)
Figure 6. Global Pharmacogenomics (PGx) Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Pharmacogenomics (PGx) Market Size by Country (M USD)
Figure 11. Pharmacogenomics (PGx) Sales Share by Manufacturers in 2023
Figure 12. Global Pharmacogenomics (PGx) Revenue Share by Manufacturers in 2023
Figure 13. Pharmacogenomics (PGx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Pharmacogenomics (PGx) Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Pharmacogenomics (PGx) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Pharmacogenomics (PGx) Market Share by Type
Figure 18. Sales Market Share of Pharmacogenomics (PGx) by Type (2019-2024)
Figure 19. Sales Market Share of Pharmacogenomics (PGx) by Type in 2023
Figure 20. Market Size Share of Pharmacogenomics (PGx) by Type (2019-2024)
Figure 21. Market Size Market Share of Pharmacogenomics (PGx) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Pharmacogenomics (PGx) Market Share by Application
Figure 24. Global Pharmacogenomics (PGx) Sales Market Share by Application (2019-2024)
Figure 25. Global Pharmacogenomics (PGx) Sales Market Share by Application in 2023
Figure 26. Global Pharmacogenomics (PGx) Market Share by Application (2019-2024)
Figure 27. Global Pharmacogenomics (PGx) Market Share by Application in 2023
Figure 28. Global Pharmacogenomics (PGx) Sales Growth Rate by Application (2019-2024)
Figure 29. Global Pharmacogenomics (PGx) Sales Market Share by Region (2019-2024)
Figure 30. North America Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Pharmacogenomics (PGx) Sales Market Share by Country in 2023
Figure 32. U.S. Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Pharmacogenomics (PGx) Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Pharmacogenomics (PGx) Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Pharmacogenomics (PGx) Sales Market Share by Country in 2023
Figure 37. Germany Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Pharmacogenomics (PGx) Sales Market Share by Region in 2023
Figure 44. China Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 50. South America Pharmacogenomics (PGx) Sales Market Share by Country in 2023
Figure 51. Brazil Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Pharmacogenomics (PGx) Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Pharmacogenomics (PGx) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Pharmacogenomics (PGx) Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Pharmacogenomics (PGx) Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Pharmacogenomics (PGx) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Pharmacogenomics (PGx) Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Pharmacogenomics (PGx) Market Share Forecast by Type (2025-2030)
Figure 65. Global Pharmacogenomics (PGx) Sales Forecast by Application (2025-2030)
Figure 66. Global Pharmacogenomics (PGx) Market Share Forecast by Application (2025-2030)
